ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT05025800. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT05025800
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 47 participants
Conditions and interventions
Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage III Grade 3 Follicular Lymphoma
- Ann Arbor Stage III Marginal Zone Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Grade 3 Follicular Lymphoma
- Ann Arbor Stage IV Marginal Zone Lymphoma
- Composite Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Refractory Follicular Lymphoma
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Richter Syndrome
Interventions
- CD47 Antagonist ALX148 Drug
- Lenalidomide Drug
- Rituximab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2021
- Primary completion
- Mar 20, 2028
- Completion
- Mar 20, 2028
- Last update posted
- Mar 19, 2026
2021 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05025800, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05025800 live on ClinicalTrials.gov.